PL172830B1 - Preparat farmaceutyczny do zwalczania bakterii PL PL PL PL PL - Google Patents

Preparat farmaceutyczny do zwalczania bakterii PL PL PL PL PL

Info

Publication number
PL172830B1
PL172830B1 PL93317972A PL31797293A PL172830B1 PL 172830 B1 PL172830 B1 PL 172830B1 PL 93317972 A PL93317972 A PL 93317972A PL 31797293 A PL31797293 A PL 31797293A PL 172830 B1 PL172830 B1 PL 172830B1
Authority
PL
Poland
Prior art keywords
hydrochloride
crystalline
active ingredient
bacteria
crystalline hydrate
Prior art date
Application number
PL93317972A
Other languages
English (en)
Polish (pl)
Inventor
Hisanori Takahashi
Yutaka Ide
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi & Co filed Critical Shionogi & Co
Publication of PL172830B1 publication Critical patent/PL172830B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cephalosporin Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL93317972A 1992-07-31 1993-07-29 Preparat farmaceutyczny do zwalczania bakterii PL PL PL PL PL PL172830B1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP20496592 1992-07-31

Publications (1)

Publication Number Publication Date
PL172830B1 true PL172830B1 (pl) 1997-12-31

Family

ID=16499234

Family Applications (2)

Application Number Title Priority Date Filing Date
PL93317972A PL172830B1 (pl) 1992-07-31 1993-07-29 Preparat farmaceutyczny do zwalczania bakterii PL PL PL PL PL
PL93299870A PL172835B1 (pl) 1992-07-31 1993-07-29 Chlorowodorek kwasu 7- ß -[(Z)-2-(2-amino-4-tiazolilo)-2-hydroksyiminoacetamido]-3-(1,2,3-triazol-4-ilo)-tiometylotio-3 -cefemo-4-karboksylowego oraz sposób jego wytwarzania, krystaliczny wodzian chlorowodorku kwasu 7- ß -(Z)-2-(2-amino-4-tiazolilo)-2-hydroksyiminoacetamido]-3-(1,2,3-triazol-4-ilo)-tiometylotio-3-ce- femo-4-karboksylowego oraz sposób jego wytwarzania PL PL PL PL PL

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL93299870A PL172835B1 (pl) 1992-07-31 1993-07-29 Chlorowodorek kwasu 7- ß -[(Z)-2-(2-amino-4-tiazolilo)-2-hydroksyiminoacetamido]-3-(1,2,3-triazol-4-ilo)-tiometylotio-3 -cefemo-4-karboksylowego oraz sposób jego wytwarzania, krystaliczny wodzian chlorowodorku kwasu 7- ß -(Z)-2-(2-amino-4-tiazolilo)-2-hydroksyiminoacetamido]-3-(1,2,3-triazol-4-ilo)-tiometylotio-3-ce- femo-4-karboksylowego oraz sposób jego wytwarzania PL PL PL PL PL

Country Status (23)

Country Link
US (1) US5407929A (cg-RX-API-DMAC7.html)
EP (1) EP0581552B1 (cg-RX-API-DMAC7.html)
KR (1) KR100245938B1 (cg-RX-API-DMAC7.html)
CN (1) CN1037683C (cg-RX-API-DMAC7.html)
AT (1) ATE165360T1 (cg-RX-API-DMAC7.html)
AU (1) AU657866B2 (cg-RX-API-DMAC7.html)
BR (1) BR9303235A (cg-RX-API-DMAC7.html)
CA (1) CA2101502A1 (cg-RX-API-DMAC7.html)
DE (1) DE69318077T2 (cg-RX-API-DMAC7.html)
ES (1) ES2115725T3 (cg-RX-API-DMAC7.html)
FI (1) FI933391A7 (cg-RX-API-DMAC7.html)
GR (1) GR3026699T3 (cg-RX-API-DMAC7.html)
HU (1) HU219637B (cg-RX-API-DMAC7.html)
IL (1) IL106516A (cg-RX-API-DMAC7.html)
MX (1) MX9304611A (cg-RX-API-DMAC7.html)
NO (1) NO303734B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ248285A (cg-RX-API-DMAC7.html)
PH (1) PH30109A (cg-RX-API-DMAC7.html)
PL (2) PL172830B1 (cg-RX-API-DMAC7.html)
RU (1) RU2118959C1 (cg-RX-API-DMAC7.html)
TW (1) TW307769B (cg-RX-API-DMAC7.html)
UA (1) UA37181C2 (cg-RX-API-DMAC7.html)
ZA (1) ZA935529B (cg-RX-API-DMAC7.html)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03007349A (es) * 2001-02-24 2003-12-04 Boehringer Ingelheim Pharma Derivados de xantina, su preparacion y su empleo como medicamentos.
AT413282B (de) * 2002-02-01 2006-01-15 Sandoz Ag Kristalline salze der 7-(((5-amino-1,2,4-thiadiazol-3-yl) (fluoromethoxy-imino)acetyl)amino)-3- ((imino-1-piperazinylmethyl)
KR20030076759A (ko) * 2002-03-21 2003-09-29 주식회사 엘지생명과학 신규 세팔로스포린 화합물 및 그의 제조 방법
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US6727277B1 (en) 2002-11-12 2004-04-27 Kansas State University Research Foundation Compounds affecting cholesterol absorption
CN101219992B (zh) 2003-02-12 2011-08-31 日产化学工业株式会社 匹伐他汀钙的晶形
BRPI0408716B1 (pt) 2003-03-27 2017-08-29 Basilea Pharmaceutica Ag. Cefalosporin in crystalline form, process for its preparation and its uses, and preparation of cephalosporin
US7501426B2 (en) * 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) * 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) * 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20080251A1 (es) * 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
NZ600394A (en) 2006-05-04 2014-04-30 Boehringer Ingelheim Int Polymorphs of a dpp-iv enzyme inhibitor
ES2733348T3 (es) * 2007-08-17 2019-11-28 Boehringer Ingelheim Int Derivados de purina para uso en el tratamiento de enfermedades relacionadas con FAP
AR071175A1 (es) 2008-04-03 2010-06-02 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
CA2735562C (en) * 2008-08-15 2017-10-17 Boehringer Ingelheim International Gmbh Dpp-4 inhibitors for wound healing
MX2011002558A (es) 2008-09-10 2011-04-26 Boehringer Ingelheim Int Terapia de combinacion para el tratamiento de diabetes y estados relacionados.
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
CA2745037C (en) 2008-12-23 2020-06-23 Boehringer Ingelheim International Gmbh Salt forms of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8(3-(r)-amino-piperidin-1-yl)-xanthine
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
CN102753161A (zh) 2009-11-27 2012-10-24 贝林格尔.英格海姆国际有限公司 基因型糖尿病患者利用dpp-iv抑制剂例如利拉利汀的治疗
CN107961377B (zh) 2010-05-05 2022-11-22 勃林格殷格翰国际有限公司 组合疗法
MX2012014247A (es) 2010-06-24 2013-01-18 Boehringer Ingelheim Int Terapia para la diabetes.
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
PL2731947T3 (pl) 2011-07-15 2019-07-31 Boehringer Ingelheim International Gmbh Podstawiona dimeryczna pochodna chinazoliny, sposób jej wytwarzania i jej zastosowanie w kompozycjach farmaceutycznych do leczenia cukrzycy typu I i II
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US20130303462A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
US20130303554A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in sirs and/or sepsis
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
WO2015128453A1 (en) 2014-02-28 2015-09-03 Boehringer Ingelheim International Gmbh Medical use of a dpp-4 inhibitor
CA3022202A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES475573A1 (es) * 1977-07-12 1980-01-16 Fujisawa Pharmaceutical Co Un procedimiento para preparar nuevos compuestos de cefem
IE65926B1 (en) * 1990-07-19 1995-11-29 Shionogi & Co Thioalkylthio cephalosporin derivatives

Also Published As

Publication number Publication date
MX9304611A (es) 1994-02-28
CN1037683C (zh) 1998-03-11
FI933391L (fi) 1994-02-01
KR100245938B1 (ko) 2000-04-01
CA2101502A1 (en) 1994-02-01
DE69318077T2 (de) 1998-10-29
HUT68602A (en) 1995-06-28
EP0581552A2 (en) 1994-02-02
CN1089948A (zh) 1994-07-27
EP0581552B1 (en) 1998-04-22
IL106516A0 (en) 1993-11-15
ZA935529B (en) 1994-02-24
PL299870A1 (en) 1994-02-07
DE69318077D1 (de) 1998-05-28
FI933391A7 (fi) 1994-02-01
ES2115725T3 (es) 1998-07-01
AU657866B2 (en) 1995-03-23
PH30109A (en) 1996-12-27
TW307769B (cg-RX-API-DMAC7.html) 1997-06-11
UA37181C2 (uk) 2001-05-15
NZ248285A (en) 1994-07-26
NO932745D0 (no) 1993-07-30
AU4422793A (en) 1994-02-03
FI933391A0 (fi) 1993-07-29
IL106516A (en) 1998-06-15
US5407929A (en) 1995-04-18
RU2118959C1 (ru) 1998-09-20
ATE165360T1 (de) 1998-05-15
HU9302194D0 (en) 1993-10-28
NO303734B1 (no) 1998-08-24
NO932745L (no) 1994-02-01
KR940005636A (ko) 1994-03-22
EP0581552A3 (en) 1994-06-01
HU219637B (hu) 2001-06-28
PL172835B1 (pl) 1997-12-31
GR3026699T3 (en) 1998-07-31
BR9303235A (pt) 1994-03-01

Similar Documents

Publication Publication Date Title
PL172830B1 (pl) Preparat farmaceutyczny do zwalczania bakterii PL PL PL PL PL
CA2155322C (en) Crystalline ceftiofur free acid
KR0180798B1 (ko) 결정성 페니실린 유도체, 그의 제법 및 용도
HU200777B (en) Process for producing crystalline cefalosporinhydrate and capsules comprising same
CS214721B2 (en) Method of making the pentahydrate of +l6r,7r+p-7-+l+lz+p-2-+l2-aminothiazol-4-yl+p-2-+l2-carboxyprop-2-oxyimino+p acetamido+p-3-+l1-piridiniummethyl+pcef-3-em-4-carboxylate
JP2002505328A (ja) 抗潰瘍医薬の硝酸塩
SE449996B (sv) (6r,7r)-7-/(z)-2-(2-aminotiazol-4-yl)-2-(2-karboxiprop-2-oxiimino)acetamidol/-3-(1-pyridiniummetyl)cef-3-em-4-karboxylat i form av en kristallin bishydroklorid farmaceutisk komposition derav samt anvendning som mellanpr
US4189479A (en) Cephalosporin esters
JPH03500536A (ja) セファロスポリン抗生物質類
JP2575590B2 (ja) トリアゾリルチオメチルチオセファロスポリン塩酸塩およびその水和物結晶ならびにそれらの製法
AU631960B2 (en) Crystalline hydrochloride of new beta-lactam antibiotic and process therefor
CA2519272C (en) Cephalosporin in crystalline form
US8470809B2 (en) Crystalline sodium salt of cephalosporin antibiotic
US3682953A (en) Substituted 5-nitrofuryl-pyrazoles
US3598812A (en) 5-nitrofuryl derivatives
JPH01301683A (ja) 新規セフエム化合物
HU210527A9 (hu) Cefalosporin kristályos hidrátja orális alkalmazáshoz és az ezt tartalmazó készítmény Az átmeneti oltalom az 1-4. és 15-17. igénypontokra vonatkozik.
LU83588A1 (de) Cephalosporinderivate
HK1085479B (en) Cephalosporin in crystalline form
SI8012497A8 (sl) Postopek za pridobivanje (6r,7r)-7-/(z)-2- (2-aminotiazol)-4-il-)-2-(karboksiprop-2-okiimino) acetamido/-3- (1-piridinium-metil)-cef-3-em-4-karboksilat pentahidratov